Pharma

Compass Pathways' Phase 3 Psilocybin Readout Raises Efficacy Questions Despite Meeting Primary Endpoint

Investor skepticism underscores challenges in demonstrating robust clinical value in psychedelic therapeutics for depression.

Novo Nordisk Strikes $812 Million Deal with Deep Apple Therapeutics to Strengthen Obesity Pipeline

The Wegovy maker announces strategic agreement worth up to $812 million with Deep Apple Therapeutics, continuing their aggressive investment into its obesity drug pipeline.

Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Receives Marketing Authorization in Australia

Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has been approved in Australia for treating early-stage Alzheimer’s disease in patients with confirmed amyloid pathology.

Breakthrough "Armoured" CAR T-Cell Therapy Shows Promising Results in Tough-to-Treat Lymphomas

In a phase 1 study, 81% of patients responded to IL18-boosted therapy, with over half achieving complete remission.

Women’s Health Therapeutics Market Enters Transformative Growth Phase

BCC Research’s findings underscore a decisive moment for women’s health therapeutics, a sector finally gaining the investment, innovation, and strategic focus it should.

UK-US Trade Deal: What's in it for Pharma?

Despite the UK securing an initial trade agreement with the US, the pharmaceutical sector remains uncertain, as the deal notably omits specific provisions for medicines, leaving the industry awaiting clearer terms regarding potential tariffs and preferential treatment.